GlassScriptPhysician profile
Todd M Reiter
NPI 1194917732
$1,995.96
in general payments reported to CMS, 2019-2025
18 companies · $338 in 2025
The $338 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $43.38 · 2021: $203 · 2022: $634 · 2023: $503 · 2024: $274 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,115.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $752.88 | 2022-2025 | Proclaim, Eterna, Octrode |
| Boston Scientific Corporation | $405.92 | 2022-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Collegium Pharmaceutical, INC. | $136.68 | 2023-2024 | Belbuca, Xtampza |
| Scilex Pharmaceuticals INC. | $110.77 | 2021-2025 | Ztlido |
| Nevro Corp. | $96.04 | 2021-2022 | |
| Virtus Pharmaceuticals LLC | $59.29 | 2023-2024 | Levorphanol Tartrate |
| Grt US Holding, INC. | $57.51 | 2022 | |
| Hikma Pharmaceuticals USA | $52.16 | 2021-2022 | |
| Si-Bone, INC. | $50.07 | 2022 | |
| Valinor Pharma, LLC | $45.73 | 2024-2025 | Movantik |
| Mindray Ds USA, INC. | $44.57 | 2023 | Te7 Max, Te X |
| Arbor Pharmaceuticals, INC. | $43.79 | 2021 | |
| Spr Therapeutics, INC | $40.00 | 2022 | |
| Globus Medical, INC. | $33.27 | 2025 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.90 | 2023 | Relistor |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $15.48 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $15.28 | 2020 | |
| Novo Nordisk INC | $12.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Reiter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.